Total hip replacement
Conditions
Interventions
FCM Group:Postoperative use of FCM injection
Blank control group:Do not use FCM injection solution.
Sponsors
Changzhou Second People's Hospital Affiliated to Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years; 2. Planned to undergo elective, primary unilateral THA; 3. Postoperative days 1–3 diagnosed with anemia: Hb levels meet the specified criteria (men Hb <130 g/L, non-pregnant women Hb <120 g/L); 4. Preoperative iron status: no restrictions but baseline transferrin levels are recorded; 5. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Known allergy to FCM or any of its excipients; 2. Active serious infection (requiring systemic antibiotic treatment); 3. Severe hepatic or renal insufficiency (as defined by laboratory criteria, such as Child-Pugh class C, eGFR < 30 ml/min/1.73m^2); 4. End-stage renal disease requiring dialysis; 5. Known hemochromatosis or other iron overload disorders; 6. Active malignant tumors (excluding non-melanoma skin cancer); 7. Planned surgery within 42 days postoperatively that may significantly affect Hb levels; 8. Preoperative diagnosis of anemia with prior intravenous iron treatment (preoperative oral iron may be allowed but must be documented); 9. Treatment with erythropoiesis-stimulating agents (ESA) within a specified period before enrollment; 10. Pregnant or breastfeeding women; 11. Investigator judgment of unsuitability for study participation (e.g., severe mental illness, expected poor compliance, life expectancy < 6 months).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin;Serum ferritin; | — |
Countries
China
Contacts
Public ContactShang Jingjing
The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University
Outcome results
None listed